UBS Reiterates Buy Rating on Boston Scientific (BSX)

Core Viewpoint - Boston Scientific Corporation (NYSE:BSX) is recognized as one of the best large-cap stocks to invest in, with UBS reiterating a Buy rating and maintaining a price target of $140 despite recent share price declines [1]. Group 1: Analyst Insights - UBS analyst Danielle Antalffy indicates that the risk/reward profile for Boston Scientific is increasingly favorable as it approaches 2026, supported by high-growth business areas sustaining momentum [2]. - The Electrophysiology (EP) division, accounting for approximately 17% of the company's estimated sales in 2025, is expected to slow in 2026; however, CEO Mike Mahoney aims to grow this division at rates higher than the market's estimated 20-25% [3]. - CEO Mahoney expresses confidence in achieving sustained double-digit growth for the WATCHMAN device, which is projected to represent about 10% of estimated sales in 2025, even ahead of the CHAMPION data readout expected in spring 2026 [4]. Group 2: Company Overview - Boston Scientific Corporation is an American biotechnology and biomedical engineering company that provides a range of devices and therapies for diagnosing and treating various diseases, including cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions [5].